Officer and Director Stock Acquisition

David Piacquad, a director at Neumora Therapeutics, Inc. (NMRA), acquired 80,000 stock options on May 27, 2026. These options, with an exercise price of $1.86 per share, are set to expire on May 26, 2036. The options vest fully on the earlier of May 27, 2027, or immediately prior to the next annual meeting following May 27, 2026. This transaction, classified as a direct acquisition, brings Mr. Piacquad's post-transaction holdings of these options to 80,000 shares.